In this review we will focus on CFTR modulators, their impact on pulmonary and intestinal microbiotas and discuss how these novel therapies may modify profoundly the gut-lung axis in CF and which long-term clinical benefit CF patients may expect. The gene discussed is CFTR; the disease is cystic fibrosis.